Novartis: Diabetes Mellitus, Type 2 trials
The registry lists 122 Diabetes Mellitus, Type 2 studies with Novartis as lead sponsor. 0 are open to participants now and 27 have results posted.
Phase 1 13Phase 2 23Phase 3 66Phase 4 30(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00138580Phase 3
- Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138567Phase 3
- Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00138554Phase 3
- Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00138541Phase 3
- Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00138515Phase 3
- Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT00136773Phase 4
- Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00120536Phase 3
- Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 DiabetesCompletedNCT00110240Phase 3
- Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00106340Phase 3
- Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00102466Phase 3
- Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesCompletedNCT00102388Phase 3
- Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00101803Phase 3
- Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00101712Phase 3
- Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%CompletedNCT00101673Phase 3
- A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 DiabetesCompletedNCT00099957Phase 2
- Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00099944Phase 3
- Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00099931Phase 3
- Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099918Phase 3
- A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00099905Phase 3
- Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00099892Phase 3
- Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099866Phase 3
- Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00099853Phase 3